Known as AMEC SPIE PharmaChem the new joint venture company is headquartered in Cergy Pontoise near Paris, and combines AMEC’s world-wide pharmaceutical expertise with SPIE’s engineering, construction and maintenance services to generate value for clients.
A comprehensive, multi-disciplinary approach, in which total responsibility for planning, design, delivery and validation of facilities for drug discovery and development, biotechnology, production and distribution, is not commonly available in France. AMEC SPIE PharmaChem will be seeking to apply its knowledge and innovative approaches early in the investment cycle when greatest value can be leveraged for clients. The joint venture will draw on its experience of projects for major pharmaceutical clients such AstraZeneca, Merck Sharp and Dohme, Pfizer and Sanofi-Synthelabo.
